| CAR-T新型联用策略治疗实体瘤研究进展 |
| |
| 引用本文： | 李梦媛,蒋小猛,孙沁怡,郭薇.CAR-T新型联用策略治疗实体瘤研究进展[J].中国药科大学学报,2023,54(4):443-449. |
| |
| 作者姓名： | 李梦媛 蒋小猛 孙沁怡 郭薇 |
| |
| 作者单位： | 中国药科大学 生命科学与技术学院,南京医科大学逸夫医院消化内科,中国药科大学 生命科学与技术学院,中国药科大学 生命科学与技术学院 |
| |
| 基金项目： | 国家自然科学基金资助项目（No.81973221）；中国肝炎防治基金会-天晴肝病研究基金资助课题（No.TQGB20210089） |
| |
| 摘 要： | 近年来，嵌合抗原受体T细胞（chimeric antigen receptor T-cell，CAR-T）疗法在血液肿瘤的治疗中取得了突破性进展，但是在实体瘤的治疗中仍然存在着诸多问题，例如CAR-T细胞渗透性差，易发生T细胞耗竭现象、脱靶效应等，故实体瘤的CAR-T疗法需要提出新的治疗策略来提升治疗效果。与单一CAR-T治疗方式相比，CAR-T联合其他肿瘤治疗手段已经在临床前及临床研究中展现出优异疗效。本篇综述总结了CAR-T联用不同肿瘤治疗方法：抗体药物、溶瘤病毒、肿瘤疫苗、纳米药物应对实体瘤治疗的研究进展，以期为开发新的CAR-T联用策略治疗实体瘤提供理论依据和新思路。
|
| 关 键 词： | 嵌合抗原受体T细胞 实体瘤 抗体药物 溶瘤病毒 肿瘤疫苗 纳米药物 |
| 收稿时间： | 2023/3/1 0:00:00 |
| 修稿时间： | 2023/5/13 0:00:00 |
Research progress of CAR-T immunotherapy in solid tumors combined with new strategies |
| |
| LI Mengyuan,JIANG Xiaomeng,SUN Qinyi and GUO Wei.Research progress of CAR-T immunotherapy in solid tumors combined with new strategies[J].Journal of China Pharmaceutical University,2023,54(4):443-449. |
| |
| Authors: | LI Mengyuan JIANG Xiaomeng SUN Qinyi and GUO Wei |
| |
| Institution: | School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,Department of Gastroenterology, Sir Run Run Hospital,Nanjing Medical University,Nanjing 211112,China,School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198 |
| |
| Abstract: | In recent years, the chimeric antigen receptor T-cell (CAR-T) therapy has achieved breakthrough progress in the treatment of hematologic malignancies. However, when it comes to solid tumors, numerous challenges persist.These include limited CAR-T cell infiltration, susceptibility to T cell exhaustion, off-target effects, and more.Thus, novel therapeutic strategies are imperative to enhance the efficacy of CAR-T therapy for solid tumors. In comparison to standalone CAR-T approaches, the combination of CAR-T with other tumor treatment modalities has demonstrated remarkable effectiveness in both preclinical and clinical research.This review article summarizes the advancements in combining CAR-T with various solid tumor treatments: antibody drugs, oncolytic viruses, tumor vaccines, and nanomedicines.The objective is to furnish a theoretical foundation and novel perspectives for the development of innovative CAR-T combination strategies tailored for solid tumor therapy. |
| |
| Keywords: | chimeric antigen receptor T-cell (CAR-T) solid tumor antibody drugs oncolytic virus cancer vaccine nano-medicine |
|
| 点击此处可从《中国药科大学学报》浏览原始摘要信息 |
| 点击此处可从《中国药科大学学报》下载免费的PDF全文 |
|
